SCHEMBL28686012

SCHEMBL28686012

CC(C)(C)OC(=O)Nc1ccc(Oc2ccnc(N)c2[N+](=O)[O-])cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.40
PDGFRA P16234 5/20 0.40
FLT1 P17948 5/20 0.40
FLT4 P35916 4/20 0.40
RET P07949 4/20 0.40
PDGFRB P09619 3/20 0.40
KIT P10721 3/20 0.40
FGFR1 P11362 3/20 0.40
RIPK2 O43353 2/20 0.40
STK10 O94804 2/20 0.40
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
EPHB2 P29323 2/20 0.40
SLC6A3 Q01959 2/20 0.40
DDR1 Q08345 2/20 0.40
MAP4K2 Q12851 2/20 0.40
PTK6 Q13882 2/20 0.40
DDR2 Q16832 2/20 0.40
AURKB Q96GD4 2/20 0.40
RIPK3 Q9Y572 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28686017 0.90 ALDH1A1 (0.43) KDRPDGFRAFLT1MAPK1PRMT1
SCHEMBL29837315 0.89 KDR (0.45) KDRPDGFRAFLT1KITMAPK14
SCHEMBL28933364 0.89 GAA (0.44) KDRPDGFRAFLT1FLT4RET
SCHEMBL2973081 0.89 KDR (0.45) KDRPDGFRAFLT1KITMAPK14
SCHEMBL28698586 0.87 PRMT1 (0.37) KDRPDGFRAFLT1ABL1SRC
SCHEMBL28697205 0.87 BRAF (0.40) KDRFLT1PRMT1BRAFALDH1A1
SCHEMBL9909777 0.87 BRAF (0.41) KDRFLT1PRMT1BRAFALDH1A1
SCHEMBL29396856 0.87 BRAF (0.41) KDRFLT1PRMT1BRAFALDH1A1
SCHEMBL29662384 0.87 KDR (0.43) KDRPDGFRAFLT1PRMT1BRAF
SCHEMBL28706536 0.87 KDR (0.43) KDRPDGFRAFLT1PRMT1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114144410-A Polyarylurea derivatives and their use in the treatment of muscular diseases 阿纳格纳斯生物技术股份有限公司 2022-03-04 CN disclosed